Wave Life Sciences Ltd. Ordinary Shares (WVE)

About Wave Life Sciences Ltd. Ordinary Shares

WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 233 institutions reported holding WVE, with 182.6 million shares worth $1.1 billion in aggregate. The largest reported holder was RA Capital Management, with 27.0 million shares worth $156.7 million. Of the 5 largest holders listed below, 3 added shares and 2 held their positions unchanged during the quarter.

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions